Virtus LifeSci Biotech Clinical Trials ETF (BBC)
|Day's Range||25.05 - 25.66|
|Inception Date||Dec 16, 2014|
The Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is managed by Virtus.
Top 10 Holdings18.35% of assets
|Akero Therapeutics, Inc.||AKRO||3.23%|
|Prothena Corporation PLC||PRTA||1.62%|
|Imago BioSciences, Inc.||IMGO||1.60%|
|Seres Therapeutics, Inc.||MCRB||1.51%|
|DICE Therapeutics, Inc.||DICE||1.51%|
|IVERIC bio, Inc.||ISEE||1.40%|
|Bicycle Therapeutics PLC||BCYC||1.39%|
|Dec 20, 2017||$0.29724||Dec 27, 2017|
|Dec 21, 2015||$0.14733||Dec 29, 2015|
These ETFs have braved the inflationary fears in the past three months and topped the S&P 500.
Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' barga...
June has proved to be a brutal month for the stock market. The combination of factors such as decades-high inflation, the Russia-Ukraine conflict and Fed?
Biotechnology sector-related exchange traded funds were in a bright spot on Friday after Bristol Myers Squibb Co. (NYSE: BMY) said it will acquire drug developers Turning Point Therapeutics (NasdaqGS: T...
Since last year, biotechnology stocks and exchange traded funds have been among the most disappointing equity assets, wilting against the backdrop of the coronavirus pandemic and in advance of broader d...
Amid a rebound in growth equities last week, biotech stocks and exchange traded funds got in on the act, and that could be a positive sign for a group that's long been slumbering. For example, the ALPS ...
While biotechnology stocks and exchange traded funds continue frustrating market participants in the early innings of 2022, investors should not lose sight of the fact this corner of the healthcare sect...
This year hasn't been kind to biotechnology stocks and related exchange traded funds. The headwinds faced by these assets were ratcheted up last week when the Biden administration revealed plans to purs...
The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.